Followers | 240 |
Posts | 12051 |
Boards Moderated | 0 |
Alias Born | 04/05/2009 |
Thursday, September 01, 2022 8:46:07 PM
Jody Staggs appointed as President and Interim CEO
CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused specialty finance company
Portfolio and pipeline remain strong as evidenced by recent closing of two $25 million credit agreements
DALLAS, Sept. 1, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Jody Staggs, Managing Director of SWK Holdings, has been promoted to the position of President, effective September 1, 2022, and will serve as interim Chief Executive Officer, effective September 30, 2022. Winston Black, Chairman and CEO, will leave his positions at SWK, effective September 30, 2022.
"Winston has guided SWK as a part of its leadership team from our founding, helping establish the company's disciplined approach to delivering creative, non-dilutive financing structures to small- and mid-sized life sciences companies. As a result of his and the team's efforts, the company has a strong foundation to move forward and focus intently on future shareholder value creation. On behalf of SWK's Board, our employees, and shareholders, I would like to thank Winston for his dedication, hard work, and numerous achievements and wish him well in his future endeavors," said Robert K. Hatcher, Member of SWK Holdings' Board of Directors.
"Jody is an ideal successor to Winston, and I am pleased he will be SWK's new President. He has been instrumental in SWK's strong portfolio performance and improved deal sourcing. Most recently, Jody and the SWK team closed two $25 million financings with Aziyo Biologics and MedMinder Systems, both highly innovative companies," Mr. Hatcher continued. "Jody's life science industry knowledge and network, credit background, and ability to identify investment opportunities should enable SWK to build on its position as a premier life science focused specialty finance company."
Mr. Staggs commented: "I want to thank Winston for his leadership over the past decade. He has transformed SWK from an OTC-listed pool of financial assets to a highly regarded, specialty life science finance company. It has been a pleasure working with and learning from Winston, and I wish him the best in this next chapter."
Mr. Staggs continued: "The SWK team is energized to build from the strong foundation that Winston helped establish. Our underlying business fundamentals are strong and current market conditions are ideal for our creative financing solutions. The existing portfolio is healthy and, with the recently announced deal closings, our investment assets currently total approximately $219 million. We will continue to capitalize on our reputation as a partner of choice for small- and mid-sized life science companies and are intently focused on improving returns for our shareholders."
Mr. Staggs, 41, was a co-founder of PBS Capital, an investment management firm that focused on pharmaceutical royalties and healthcare equities and was a predecessor to SWK's specialty finance business. He joined SWK Holdings in August 2015 and was promoted to Managing Director in January 2020. Prior to joining SWK, Mr. Staggs was a Vice President of Investments at Annandale Capital as well as being the first employee at Dallas-based hedge fund, Alistair Capital. Mr. Staggs was a Senior Portfolio Analyst at Highland Capital where he worked on the firm's healthcare multi-strategy and public equity groups. Mr. Staggs began his career as an equity research associate at Raymond James, where he covered healthcare companies. He was a Walton Scholar and on the Dean's List at the University of Arkansas where he graduated with a B.A. in Finance. He has earned the right to use the Chartered Financial Analyst designation.
About SWK Holdings Corporation
SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases, and typically range in size from $5.0 million to $25.0 million. SWK also owns Enteris BioPharma, whose Peptelligence® and ProPerma® drug delivery technologies create oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its finance portfolio by actively creating a wholly owned portfolio of milestones and royalties through licensing activities. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.
https://www.prnewswire.com/news-releases/swk-holdings-announces-leadership-transition-301616147.html
"Someone said it takes 30 years to be an instant success" - Gabriel Barbier-Mueller, Founder and CEO of Harwood International
Recent SWKH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:31:36 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 10:26:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:09:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:09:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:08:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:08:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:30:39 PM
- SWK Holdings Corporation Announces Financial Results for Third Quarter 2023 • PR Newswire (US) • 11/09/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:06:24 PM
- SWK Holdings Corporation to Report Third Quarter 2023 Financial Results • PR Newswire (US) • 11/06/2023 09:05:00 PM
- SWK Holdings Corporation Announces B. Riley Securities Exercises Option to Purchase Approximately $3 Million in Additional Unsecured Senior Notes • PR Newswire (US) • 10/30/2023 12:00:00 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 12:00:40 PM
- SWK Holdings Corporation Increases Revolving Credit Facility to $60 Million • PR Newswire (US) • 10/11/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:33:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:33:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:33:10 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 10/03/2023 08:08:52 PM
- SWK Holdings Corporation Announces Closing of Public Offering of Senior Unsecured Notes Due 2027 • PR Newswire (US) • 10/03/2023 08:05:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 10/03/2023 07:12:07 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 09/29/2023 09:20:08 PM
- SWK Holdings Corporation Announces Pricing of Public Offering of Senior Unsecured Notes Due 2027 • PR Newswire (US) • 09/28/2023 10:34:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM